{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+duration&page=34",
    "query": {
      "intervention": "Phase duration",
      "page": 34
    },
    "page_size": 10
  },
  "pagination": {
    "page": 34,
    "page_size": 10,
    "total_count": 3754,
    "total_pages": 376,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+duration&page=35&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+duration&page=33&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T05:23:48.462Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07040891",
      "title": "A Pilot Trial of \"Just ASK™\" to Increase Discussions About Breast Cancer Clinical Trials",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Just ASK training",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2026-02-01",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-10-31T05:23:48.462Z",
      "location_count": 1,
      "location_summary": "Plainsboro, New Jersey",
      "locations": [
        {
          "city": "Plainsboro",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07040891"
    },
    {
      "nct_id": "NCT03093909",
      "title": "Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Neoplasm of Bone and Articular Cartilage",
        "Malignant Neoplasms of Female Genital Organs",
        "Malignant Neoplasms of Independent (Primary) Multiple Sites",
        "Malignant Neoplasms of Lip Oral Cavity and Pharynx",
        "Malignant Neoplasm of Male Genital Organs",
        "Malignant Neoplasms of Mesothelial and Soft Tissue",
        "Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma",
        "Malignant Neoplasms of Thyroid and Other Endocrine Glands",
        "Malignant Neoplasms of Urinary Tract",
        "Melanoma and Other Malignant Neoplasms of Skin"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "12 Years to 50 Years"
      },
      "enrollment_count": 44,
      "start_date": "2017-11-22",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-10-31T05:23:48.462Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03093909"
    },
    {
      "nct_id": "NCT06613217",
      "title": "Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed Adult AML"
      ],
      "interventions": [
        {
          "name": "zelenirstat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pacylex Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2025-03-03",
      "completion_date": "2026-09-01",
      "has_results": false,
      "last_update_posted_date": "2025-03-10",
      "last_synced_at": "2026-10-31T05:23:48.462Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06613217"
    },
    {
      "nct_id": "NCT01553071",
      "title": "Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Fenretinide (4-HPR) plus Intravenous Safingol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "South Plains Oncology Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2016-11",
      "completion_date": "2020-12",
      "has_results": false,
      "last_update_posted_date": "2022-03-31",
      "last_synced_at": "2026-10-31T05:23:48.462Z",
      "location_count": 3,
      "location_summary": "Dallas, Texas • Lubbock, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Lubbock",
          "state": "Texas"
        },
        {
          "city": "Lubbock",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01553071"
    },
    {
      "nct_id": "NCT05535192",
      "title": "TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Stage III Breast Cancer",
        "Breast Cancer Female",
        "Stage I Breast Cancer",
        "Stage II Breast Cancer"
      ],
      "interventions": [
        {
          "name": "THRIVE",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Health Education Support Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "65 Years and older · Female only"
      },
      "enrollment_count": 270,
      "start_date": "2023-03-20",
      "completion_date": "2028-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-10-31T05:23:48.462Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Cleveland, Ohio • Pittsburgh, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "State College",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05535192"
    },
    {
      "nct_id": "NCT05230511",
      "title": "Intravesical LGG VS Saline Bladder Wash RCT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Spinal Cord Injuries",
        "Neurogenic Bladder"
      ],
      "interventions": [
        {
          "name": "Lactobacillus RhamnosusGG",
          "type": "DRUG"
        },
        {
          "name": "Saline bladder wash",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medstar Health Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2022-06-13",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-29",
      "last_synced_at": "2026-10-31T05:23:48.462Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05230511"
    },
    {
      "nct_id": "NCT01570036",
      "title": "Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Herceptin",
          "type": "DRUG"
        },
        {
          "name": "NeuVax vaccine",
          "type": "DRUG"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "George E. Peoples",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 275,
      "start_date": "2013-05-21",
      "completion_date": "2018-09-28",
      "has_results": true,
      "last_update_posted_date": "2020-12-02",
      "last_synced_at": "2026-10-31T05:23:48.462Z",
      "location_count": 29,
      "location_summary": "Beverly Hills, California • Santa Monica, California • Santa Rosa, California + 22 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01570036"
    },
    {
      "nct_id": "NCT01027234",
      "title": "This Study Will Assess the Safety and Tolerability of AZD8418 After Single Increasing Oral Doses",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "AZD8418",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 40,
      "start_date": "2009-11",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2010-05-26",
      "last_synced_at": "2026-10-31T05:23:48.462Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01027234"
    },
    {
      "nct_id": "NCT01138085",
      "title": "Safety, Pharmacokinetics (PK) of AKT and MEK Combination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "GSK1120212",
          "type": "DRUG"
        },
        {
          "name": "GSK2141795",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2010-05-04",
      "completion_date": "2014-11-19",
      "has_results": false,
      "last_update_posted_date": "2017-11-13",
      "last_synced_at": "2026-10-31T05:23:48.462Z",
      "location_count": 10,
      "location_summary": "Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01138085"
    },
    {
      "nct_id": "NCT07565155",
      "title": "Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Adenocarcinoma",
        "Homologous Recombination Deficiency"
      ],
      "interventions": [
        {
          "name": "Lorigerlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2027-01-01",
      "completion_date": "2032-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-31T05:23:48.462Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07565155"
    }
  ]
}